Eisen-Sandoz

Eisen-Sandoz may be available in the countries listed below.

Ingredient matches for Eisen-Sandoz

Ferrous Gluconate

Ferrous Gluconate is reported as an ingredient of Eisen-Sandoz in the following countries:

• Germany

International Drug Name Search

Parasin

Parasin may be available in the countries listed below.

Ingredient matches for Parasin

Albendazole

Albendazole is reported as an ingredient of Parasin in the following countries:

• Brazil

International Drug Name Search

Corvert

In the US, Corvert (ibutilide systemic) is a member of the drug class group III antiarrhythmics and is used to treat Atrial Fibrillation and Atrial Flutter.

US matches:

• Corvert

Ingredient matches for Corvert

Ibutilide

Ibutilide fumarate (a derivative of Ibutilide) is reported as an ingredient of Corvert in the following countries:

• Austria


• Canada


• Finland


• France


• Greece


• Italy


• Netherlands


• Norway


• Sweden


• Switzerland


• United States

International Drug Name Search

Cryptococcal Meningitis, Immunosuppressed Host Medications

Drugs associated with Cryptococcal Meningitis, Immunosuppressed Host

The following drugs and medications are in some way related to, or used in the treatment of Cryptococcal Meningitis, Immunosuppressed Host. This service should be used as a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

Learn more about Cryptococcal Meningitis, Immunosuppressed Host

Medical Encyclopedia:

• Meningitis - cryptococcal

Drug List:

Ambisome

Amphocin

Ancobon

Diflucan

Fungizone

Fungizone-For-Tissue-Culture

rotigotine transdermal

Generic Name: rotigotine (transdermal) (roe TIG oh teen)

Brand Names: Neupro

What is rotigotine?

Rotigotine has some of the same effects as a chemical called dopamine, which occurs naturally in your body. Low levels of dopamine in the brain are associated with Parkinson's disease.

Rotigotine is used to treat early signs and symptoms of Parkinson's disease.

Rotigotine may also be used for purposes other than those listed in this medication guide.

Rotigotine skin patches were withdrawn from the U.S. market in April 2008.

What is the most important information I should know about rotigotine?

Rotigotine skin patches were withdrawn from the U.S. market in April 2008.

Do not stop using rotigotine without first talking to your doctor. You may need to use less and less before you stop using the patches completely. Stopping suddenly can cause fever, stiff muscles, confusion, sweating, and fast or uneven heartbeats. Rotigotine may cause you to fall asleep during normal daytime activities such as working, talking, eating, or driving. You may fall asleep suddenly, even after feeling alert. Tell your doctor if you have any problems with daytime sleepiness or drowsiness. If you are unsure of how this medicine will affect you, be careful if you drive or do anything that requires you to be awake and alert.

Call your doctor at once if you have serious side effects such as extreme drowsiness, falling asleep suddenly, breathing problems, severe or sudden headache, hallucinations, chest pain, swelling, fainting, or restless muscle movements in your eyes, tongue, jaw, or neck.

You may have increased sexual urges, intense or unusual urges to gamble, or other intense urges while taking rotigotine. Talk with your doctor if you believe you have any intense or unusual urges while you are using rotigotine.

Avoid getting up too fast from a sitting or lying position, or you may feel dizzy. Get up slowly and steady yourself to prevent a fall.

The rotigotine transdermal patch may burn your skin if you wear the patch during an MRI (magnetic resonance imaging). Remove the patch before undergoing such a test.

What should I discuss with my health care provider before using rotigotine?

Do not use this medication if you are allergic to rotigotine, povidone, or silicone.

Before using rotigotine, tell your doctor if you have:

• 
  

  asthma or any allergies;

  
  


• 
  

  heart disease or congestive heart failure;

  
  


• 
  

  high blood pressure;

  
  


• 
  

  epilepsy or other seizure disorder; or

  
  


• 
  

  tremors (dyskinesia) or uncontrolled muscle movements.

  
  

FDA pregnancy category C. Rotigotine may be harmful to an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant during treatment. Rotigotine may pass into breast milk and could harm a nursing baby. Do not use this medication without telling your doctor if you are breast-feeding a baby. Rotigotine may cause you to fall asleep during normal daytime activities such as working, talking, eating, or driving. You may fall asleep suddenly, even after feeling alert. Tell your doctor if you have any problems with daytime sleepiness or drowsiness. If you are unsure of how this medicine will affect you, be careful if you drive or do anything that requires you to be awake and alert.

You may have increased sexual urges, intense or unusual urges to gamble, or other intense urges while using rotigotine. It is not known whether the medicine actually causes this effect. Talk with your doctor if you believe you have any intense or unusual urges while you are using rotigotine.

Some people using medicines for Parkinson's disease have developed skin cancer (melanoma). However, people with Parkinson's disease may have a higher risk than most people for developing melanoma. Talk to your doctor about your specific risk and what skin symptoms to watch for. You may need to have regular skin exams.

The rotigotine transdermal patch may burn your skin if you wear the patch during an MRI (magnetic resonance imaging). Remove the patch before undergoing such a test.

How should I use rotigotine?

Use this medication exactly as it was prescribed for you. Do not apply more patches or wear them for longer than recommended by your doctor. Follow the instructions on your prescription label.

Rotigotine transdermal comes with patient instructions for safe and effective use. Follow these directions carefully. Ask your doctor or pharmacist if you have any questions.

Never cut or tear a rotigotine patch.

Apply a rotigotine patch once daily to clean, dry, intact skin. The best place to wear the patch is on your stomach, hip, thigh, upper arm, shoulder, or the lower left or right side of your back.

If you plan to wear a patch on an area of skin that is hairy, shave the area at least 3 days before wearing a patch on it. Choose another hairless skin area to wear your patch during that time.

Do not place a rotigotine patch on red, irritated, or broken skin.

Avoid placing the patch where it will be rubbed by tight clothing. Do not place the patch in the folds of your skin. The patch should remain flat on the skin at all times. Take care to avoid accidentally removing the patch while showering or during physical activity.

The rotigotine patch is usually worn for 24 hours around the clock.

Use a different place on your body each day when putting on a new patch. Do not wear a patch on the same place twice within 14 days.

Always wash your hands after handling or applying a rotigotine patch.

When it is time to change your patch, remove the worn patch slowly to prevent skin irritation. Wash the area with soap and water. Use baby oil to remove any excess adhesive from your skin. Do not use rubbing alcohol, nail polish remover, or other solvents that can irritate the skin.

Do not stop using rotigotine without first talking to your doctor. You may need to use less and less before you stop using the patches completely. Stopping suddenly can cause fever, stiff muscles, confusion, sweating, and fast or uneven heartbeats. Store rotigotine patches at room temperature away from moisture and heat. Keep each patch in its original pouch until you are ready to use it. The pouch should open easily. Do not use scissors to cut open the pouch.

What happens if I miss a dose?

Apply a skin patch as soon as you remember. If it is almost time to apply your next patch, skip the missed dose and apply a patch at your next regularly scheduled time. Do not use extra patches to make up the missed dose.

If a skin patch falls off, try sticking it back on. You may use bandage tape around the edges to hold the patch in place.

What happens if I overdose?

Seek emergency medical attention if you think you have used too much of this medicine.

An overdose of rotigotine is not likely unless you wear more than one patch at a time, or if you forget to remove a patch before putting on a new one.

What should I avoid while using rotigotine?

Avoid touching your eyes after handling a rotigotine patch.

Do not use any cream, lotion, ointment, oil, or powder on the skin where you plan to apply a skin patch. The patch may not stick well to the skin.

Avoid applying heat to the skin where the patch is worn, because it may increase the amount of medicine your body absorbs. Heat sources include hot tubs, heating pads, heat lamps, saunas, heated water beds, and direct sunlight. Rotigotine can cause side effects that may impair your thinking or reactions. Be careful if you drive or do anything that requires you to be awake and alert.

Avoid getting up too fast from a sitting or lying position, or you may feel dizzy. Get up slowly and steady yourself to prevent a fall.

Rotigotine side effects

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat. Call your doctor at once if you have any of these serious side effects:

• 
  

  extreme drowsiness, falling asleep suddenly, even after feeling alert;

  
  


• 
  

  nausea, sweating, feeling light-headed, fainting;

  
  


• 
  

  breathing problems;

  
  


• 
  

  severe headache, blurred vision, trouble concentrating, chest pain, numbness, seizure;

  
  


• 
  

  hallucinations;

  
  


• 
  

  swelling in your hands or feet; or

  
  


• 
  

  restless muscle movements in your eyes, tongue, jaw, or neck.

  
  

Less serious side effects may include:

• 
  

  weight gain;

  
  


• 
  

  swelling, redness, or itching where the patch was applied.

  
  


• 
  

  urinating more than usual;

  
  


• 
  

  runny nose;

  
  


• 
  

  diarrhea, loss of appetite;

  
  


• 
  

  feeling dizzy, tired, or weak;

  
  


• 
  

  mild drowsiness or sleepiness;

  
  


• 
  

  headache;

  
  


• 
  

  sleep problems (insomnia);

  
  


• 
  

  blurred vision; or

  
  


• 
  

  swelling in your hands or feet.

  
  

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Rotigotine Dosing Information

Usual Adult Dose for Parkinson's Disease:

Initial: 2 mg patch applied topically every 24 hours

Maintenance: Dosage may be increased weekly by 2 mg per 24 hours if tolerated and if additional therapeutic effect is needed. The lowest effective dose is 4 mg per 24 hours.

Maximum: 6 mg per 24 hours

What other drugs will affect rotigotine?

Tell your doctor if you regularly use other medicines that make you sleepy (such as cold or allergy medicine, narcotic pain medicine, sleeping pills, muscle relaxers, and medicine for seizures, depression, or anxiety). They can add to sleepiness caused by rotigotine.

There may be other drugs that can affect rotigotine. Tell your doctor about all the prescription and over-the-counter medications you use. This includes vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start using a new medication without telling your doctor.

More rotigotine resources

• Rotigotine Side Effects (in more detail)
• Rotigotine Dosage
• Rotigotine Use in Pregnancy & Breastfeeding
• Rotigotine Drug Interactions
• Rotigotine Support Group
• 5 Reviews for Rotigotine - Add your own review/rating

Compare rotigotine with other medications

• Parkinson's Disease

Where can I get more information?

• Your pharmacist can provide more information about rotigotine.

See also: rotigotine side effects (in more detail)

Azulfin

Azulfin may be available in the countries listed below.

Ingredient matches for Azulfin

Sulfasalazine

Sulfasalazine is reported as an ingredient of Azulfin in the following countries:

• Brazil

International Drug Name Search

Ralenost

Ralenost may be available in the countries listed below.

Ingredient matches for Ralenost

Alendronic Acid

Alendronic Acid is reported as an ingredient of Ralenost in the following countries:

• Latvia

International Drug Name Search

Zymar

Zymar is a brand name of gatifloxacin ophthalmic, approved by the FDA in the following formulation(s):

ZYMAR (gatifloxacin - solution/drops; ophthalmic)

• 
  Manufacturer: ALLERGAN
  
  Approval date: March 28, 2003
  
  Strength(s): 0.3% ^[RLD][AT]

Has a generic version of Zymar been approved?

A generic version of Zymar has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Zymar and have been approved by the FDA:

gatifloxacin solution/drops; ophthalmic

• 
  Manufacturer: APOTEX CORP
  
  Approval date: August 19, 2011
  
  Strength(s): 0.3% ^[AT]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zymar. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  8-alkoxyquinolonecarboxylic acid hydrate with excellent stability and process for producing the same
  Patent 5,880,283
  Issued: March 9, 1999
  Inventor(s): Matsumoto; Toyomi & Hara; Masamoto & Miyashita; Kunio & Kato; Yukihiro
  Assignee(s): Kyorin Pharmaceutical Co., Ltd.
  The invention provides 1-cyclopropyl-6-fluoro-1,4- dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3- quinolinecarboxylic acid sesquihydrate with excellent stability represented by a following formula (1), ##STR1## and process for producing the same.
  
  Patent expiration dates:
  
  
  • December 5, 2015
    
  
  
  
  • June 5, 2016
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Aqueous liquid pharmaceutical composition comprised of gatifloxacin
  Patent 6,333,045
  Issued: December 25, 2001
  Inventor(s): Yasueda; Shinichi & Inada; Katsuhiro
  Assignee(s): Senju Pharmaceutical Co., Ltd.
  Kyorin Pharmaceutical Co., Ltd.
  There is provided an aqueous liquid pharmaceutical composition which comprises Gatifloxacin (chemical nomenclature: (.+-.)-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazi nyl)-4-oxo-3-quinoline carboxylic acid) or its salt and disodium edetate. Further, there are provided a method for raising corneal permeability of Gatifloxacin, a method for preventing precipitation of Gatifloxacin crystals, and a method for preventing coloration of Gatifloxacin by incorporating disodium edetate into an aqueous liquid preparation containing Gatifloxacin or its salt.
  
  Patent expiration dates:
  
  
  • August 20, 2019
    
    ✓ 
    Drug product
  
  
  
  • February 20, 2020
    
    ✓ 
    Pediatric exclusivity
  
  

See also...

• Zymar Drops Consumer Information (Wolters Kluwer)
• Zymar Consumer Information (Cerner Multum)
• Zymar Advanced Consumer Information (Micromedex)
• Zymar eent AHFS DI Monographs (ASHP)
• Gatifloxacin Drops Consumer Information (Wolters Kluwer)
• Gatifloxacin ophthalmic Consumer Information (Cerner Multum)
• Gatifloxacin Ophthalmic Advanced Consumer Information (Micromedex)
• Gatifloxacin eent AHFS DI Monographs (ASHP)

Microcid

Microcid may be available in the countries listed below.

Ingredient matches for Microcid

Hydrogen Peroxide

Hydrogen Peroxide is reported as an ingredient of Microcid in the following countries:

• Norway

Hydrogen Peroxide 1 per cent (a derivative of Hydrogen Peroxide) is reported as an ingredient of Microcid in the following countries:

• Sweden

International Drug Name Search

Simvastatin Merck NM

Simvastatin Merck NM may be available in the countries listed below.

Ingredient matches for Simvastatin Merck NM

Simvastatin

Simvastatin is reported as an ingredient of Simvastatin Merck NM in the following countries:

• Finland

International Drug Name Search

Trichopol

Trichopol may be available in the countries listed below.

Ingredient matches for Trichopol

Metronidazole

Metronidazole is reported as an ingredient of Trichopol in the following countries:

• Georgia


• Latvia


• Lithuania


• Russian Federation

International Drug Name Search